The role of progesterone in regulating reproductive physiology in animals is complex and difficult to evaluate because the direction and extent of the effects of progesterone depend on the endogenous hormonal milieu. The actions of progesterone typically require previous exposure to 17β-oestradiol (E 2 ) because E 2 regulates nuclear progesterone receptor expression.
gland, the role of progesterone with respect to controlling lactotroph proliferation and prolactin (PRL) secretion is controversial. 2 Progesterone can facilitate the effect of E 2 , although it can also prevent oestradiol-induced PRL surges and PRL gene expression during prolonged progesterone treatment. 1 This can also be observed in the experimental model of prolactinoma generated in female rats by chronic treatment with diethylstilbestrol (DES), a synthetic oestrogen, where cotreatment with progesterone antagonises the proliferative effects of DES on lactotrophs, thereby decreasing tumour size and serum PRL levels. 3 Therefore, it appears that progesterone serves an antiproliferative and protective role in the pituitary gland. 3, 4 On the other hand, in E 2 -primed animals, acute progesterone treatment increases PRL release [5] [6] [7] and may stimulate proliferation depending on the hormonal environment and type of receptor involved. 8, 9 However, it is important to recognise that progesterone also exerts an indirect impact on PRL secretion through regulating the activity of tyrosine hydroxylase (TH) in the hypothalamus, the main enzyme involved in the biosynthesis of dopamine, 4, [10] [11] [12] which is the major inhibitory regulator of PRL secretion.
Aside from other well-documented genomic effects, progesterone exerts rapid "nongenomic" actions through activation of membrane progesterone receptors (mPRs). These actions are relatively unaffected by inhibitors of transcription, as mimicked by steroids coupled to nonpermeant cell membrane molecules and persist in cells that do not express the classic genomic progesterone receptor. 13 The mPRs belong to the progestin and adipoQ receptor (PAQR) family and were first identified in teleost fish, 14 although it was later discovered that 5 subtypes (mPRα, mPRβ, mPRγ, mPRδ and mPRε) are found in tissues of several mammalian species, including humans. [15] [16] [17] [18] [19] [20] [21] [22] [23] These receptors contain 7 transmembrane domains, display high-affinity progesterone binding and rapidly activate G proteins during their downstream signalling pathways following progestin binding. 19 Several studies have demonstrated that mPRα, mPRβ and mPRγ activation induces inhibitory G protein (Gi) signalling pathways, thereby decreasing adenylyl cyclase activity and cellular cAMP accumulation. 17, 18, 24 mPRδ and mPRε, on the other hand, are coupled to stimulatory to G proteins (Gs) and increase cAMP accumulation after activation. 15 Moreover, mPRα and mPRβ are expressed more strongly in different tissues of mammals such as the rat and mouse brain, 21, 22 as well as in reproductive tissues. 16 mPRγ is largely expressed in the lung, liver, kidney and fallopian tubes; 25 meanwhile, mPRδ and mPRε have been described in the human brain and pituitary. 15 Among the mPRs subtypes, mPRα is the most extensively characterised in vertebrates. Studies have revealed that mPRα is involved in the regulation by progesterone of numerous functions, 26 including uterine function in humans 16 and the inhibition of gonadotrophin-releasing hormone (GnRH) release in rodents.
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mPRα is also thought of as an intermediary of progesterone antitumourigenic effects in ovarian cancer cells, which may provide a new treatment option for patients undergoing advanced stage ovarian cancer therapy. 27 Although there is substantial evidence that progesterone initiates rapid, cell-surface actions in several cell types through mPRs, there are no published studies reporting the exact role of these receptors in the pituitary gland.
In the present study, we hypothesise that mPRs mediate rapid actions of progesterone in the pituitary gland. Accordingly, to test this, we studied the expression of mPRs in rat pituitaries and in rat pituitary tumour-derived GH3 cells and investigated cell-type localisation, as well as the role of the mPR most likely involved in mediating the actions of progesterone in the rat pituitary.
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| MATERIAL S AND ME THODS
| Chemicals and reagents
Chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA) unless otherwise stated, including DES or (E)-3,4-bis(4-hydroxyphenyl)-3-hexene, a synthetic oestrogen. Progesterone was purchased from Steraloids (Newport, RI, USA). Org OD 02-0 was obtained from Organon (Oss, the Netherlands). R5020 was purchased from GE Healthcare (Piscataway, NJ, USA). Although Org OD 02-0 was initially described as a human mPRα agonist, its selectivity on mPRs in rat cells has been also demonstrated in the rat brain and 
| Animals
Adult female Sprague-Dawley (SD) rats (3 months old, 250 ± 30 g)
were maintained at under a 12:12 hour light/dark cycle (lights on 07.00 hours) at 22 ± 2°C. Cycling rats were monitored daily, by vaginal smears, during 4-5-day oestrous cycles, and killed during dioestrous. Anterior pituitary glands were removed within minutes after decapitation.
The animals were provided with food and water ad libitum. 
| Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from anterior pituitaries of female adult SD rats in dioestrus with Trizol reagent (Ambion, Life Technologies, Grand
Island, NY, USA) in accordance with the manufacturer′s instructions.
RNA purity and quantity were determined using a NanoDrop ND- values of each receptor. The expression of nPRs was analysed using a primer set to amplify total PRs and a second primer set to amplify only PR-B.
| Ex vivo assay
Female SD rats in dioestrus were killed by decapitation and anterior pituitaries were collected. Anterior pituitaries were cut in pieces and incubated in 500 μL of Dulbecco's modified Eagle's medium (DMEM)
supplemented with 15% horse serum, 2.5% fetal bovine serum, 1:1000) for 1 hour. Then, the glass coverslips were mounted with fluoromount (Sigma-Aldrich) containing 4′,6-diamidino-2-phenylindole (DAPI).
Control cells were incubated with the corresponding normal serum or immunoglobulin (Ig)G subtype instead of primary antibody.
Images were obtained using the inverted confocal laser scanning microscope FluoView FV 1000 (Olympus, Tokyo, Japan). The analysis of confocal microscopy images was performed using the fv10-asw 1.6 viewer (Olympus).
| Flow cytometry
Control rats were killed, and anterior pituitary glands were re- containing trypsin (2.5 mg mL -1 ; Gibco) and reseeded at 20% of the original density, and 4 subcultures were made before each experiment. In some experiments, the culture media was replaced with serum-free DMEM before experimentation.
| Culture of GH3 cells
| Preparation of plasma membranes
GH3 cells were subcultured in 15-cm culture dishes until they were 90% confluent and then harvested with a cell scraper and col-
oerythritol, pH 7.6) with a protease inhibitor cocktail (Thermo Fisher Scientific). Cells were rinsed twice followed by a 5-minute centrifugation at 1000 g for at 4°C and cell pellets resuspended in freshly prepared ice-cold HAED buffer. Cells were lysed by sonication for 10 seconds and then centrifuged at 1000 g at 4°C for 7 minutes to remove any nuclear and heavy mitochondrial material (nuclear fraction). The supernatant was centrifuged at 20 000 g at 4°C for 20 minutes to obtain the plasma membrane fraction, which was resuspended with HAED buffer.
| Single-point competitive binding assay
A single-point competitive assay was conducted as described previously 19 using GH3 cells. Briefly, plasma membranes were incubated and radioactivity bound to the filters was measured by scintillation counting (model LS6000; Beckman Coulter, Fullerton, CA, USA).
The displacement of radiolabelled steroid binding by the progestin competitors was expressed as a percentage of the maximum specific
| Western blot analysis of membrane progesterone receptors
GH3 plasma membranes were solubilised and mixed with 4× Lane
Marker Reducing Sample Buffer (Thermo Fisher Scientific) boiled for 10 minutes and run on a 15% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel (15 μg protein per lane).
Proteins were then transferred onto nitrocellulose membranes at 4°C
for 1 hour and blocked in PBS-Tween-20 with 5% nonfat dried milk.
Membranes were incubated overnight at 4°C in PBS + Odyssey®
Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) containing previously validated polyclonal antibodies 15, 16, 25, 31 : mPRα (dilution 1:500); mPRβ, mPRγ and mPRε (dilution 1:1000), as well as antibodies directed against progesterone receptor membrane component 1 (PGRMC1) (dilution 1:1000) or nuclear progesterone receptor (nPR) (dilution 1:1000) ( Table 2 ). The nitrocellulose membranes were then incubated with fluorescence-conjugated secondary antibodies (dilution 1:10 000) (LI-COR Biosciences) for 1 hour at room temperature washed 3 times with PBS and scanned with the Odyssey® Infrared Imaging System (LI-COR Biosciences).
| Immunocytochemical analysis of progesterone receptors
The presence of mPRs in 
| Pertussis toxin assay
Pertussis toxin (List Biological Laboratories, Inc., Campbell, CA, The PRL concentration in cell supernatants was measured using a specific Rat Prolactin EIA kit in accordance with the manufacturer's instructions (Cayman Chemicals). Phosphorylated ERK was normalised to total ERK using imagej software (NIH, Bethesda, MD, USA).
| cAMP assay
| Active transforming growth factor (TGF)
β1 detection 
| Inhibitor treatments
Cells were pretreated with Pertussis toxin (2.5 μg mL 
USA) was used to pretreat cells for 1 hour prior to treatment with Org OD 02-0. At the end of the treatment periods, active TGFβ1 levels were measured by ELISA as described previously.
| Statistical analysis
Results are expressed as the mean ± SEM. Experiments were repeated between 3 and 5 times, with at least 3 replicates. P4, Org OD 02-0 and R5020 treatments results were evaluated by One-way ANOVA followed by Tukey′s post-hoc test. Two-way ANOVA was performed when the effects of 2 factors (progestin treatments and PTX, inhibitors treatments or siRNA treatment) were evaluated, followed by Bonferroni′s post-hoc multiple comparison test. P < .05
was considered statistically significant. The data set was transformed when required and analysed using prism, version 5 (GraphPad Software, San Diego, CA).
| RE SULTS
| Expression of nPRs and mPRs by qRT-PCR in female rat pituitary
The mRNA expression of each progesterone receptor was assayed 
| mPRα is expressed in lactotrophs, gonadotrophs and somatotrophs
With mPRα being probably the most abundant mPR found in the pituitary, we next performed double immunocytochemistry (ICC)
to assay mPRα protein coexpression with PRL, LH and GH cells.
Immunostaining of mPRα was detected in lactotrophs, gonadotrophs
and somatotrophs (Figure 2 ).
To explore the percentage of mPRα-positive cells among the total anterior pituitary cells and among the lactotroph population, we ran double indirect immunofluorescence assays for both mPRα and PRL. Using an approach that preserves the integrity of the cell membrane, 32 we detected the percentage of anterior pituitary cells and lactotrophs expressing mPRα by flow cytometry (Figure 3) . The results revealed that 42.1 ± 11.6% of total anterior pituitary cells were mPRα-positive ( Figure 3A) and 63% of the mPRα-positive cells were also PRL-positive (37% of the mPRα-positive cells were nonlactotrophs) ( Figure 3B ).
| Effect of progesterone and specific mPR agonist Org OD 02-0 on PRL secretion
To evaluate the role of mPRα on lactotroph function, the effect of progesterone and Org OD 02-0, a selective mPR agonist with no nPR 
| mPRs are expressed in the GH3 cell line
To clarify the cellular mechanisms behind mPRα activity, studies were performed using the GH3 cell line (CCL-82.1). The GH3 cell line derives from a pituitary tumour carried in a 7-month-old female
Wistar-Furth rat and produces both growth hormone and prolactin, providing an excellent tool to study lactotroph-like function and signalling. 34 First, mRNA expression of mPRs was examined in the GH3 cell line by quantitative RT-PCR ( Figure 5 ). Based on ΔCT data obtained, mPRα mRNA appears to have the highest expression among mPRs ( Figure 5A ), followed by mPRβ and mPRε. Then, using GH3-cell plasma membrane extracts, the protein expression of mPRs, nPRs and the progesterone receptor membrane component-
(PGRMC1) was detected (
Figure 5B) using specific mPR, nPR and PGRMC1 antibodies (Table 2 ) by western blotting. Immunoreactive bands of mPRβ (~40 kDa) and PGRMC1 (~28 kDa) were observed.
However, although denaturing conditions were used (SDS-PAGE), mPRα, mPRγ and mPRε bands were detected at ~80 kDa. These molecular weights have been reported previously, 15, 22, 23, 31 and were suggested to be a result of dimer formation. Although further work is required to establish whether this is the case, the reduction observed in the staining for this band after siRNA to mPRα in GH3 cells (Figure 8 ) is consistent with it being mPRα. The presence of 2 bands of predicted sizes for nPRs (88-110 kDa) was detected in cell lysates (c) and weak bands were observed in membrane extracts (m). In addition, mPR expression and localisation were examined by ICC ( Figure 5C ). We found protein expression of mPRα, mPRβ, mPRγ, mPRε and PGRMC1 in GH3 cells but not mPRδ, probably reflecting its low mRNA levels.
| Involvement of second messengers in mPRα-mediated progestin effects on PRL secretion
The 
| TGFβ1 involvement in mPRα-mediated effects
TGFβ1 is a multifunctional and ubiquitous cytokine, well known for its ability to inhibit cell proliferation in epithelial cells. In the pituitary, TGFβ1 and its receptor TβRII are expressed in lactotrophs, and
TGFβ1 is a known inhibitor of lactotroph function. 35, 36 Stimulatory effects of progesterone on TGFβ1 activation have been reported previously in different tissues [37] [38] [39] ; however, the receptors and mechanisms involved were not investigated in those studies. To explore the possible TGFβ1-mediated action in PRL inhibition induced by mPRα stimulation, active TGFβ1 levels after progestin stimulation in GH3 cells were measured by a specific ELISA (Figure 7 ). Treatment with either P4 or Org OD 02-0 significantly increased active TGFβ1 levels after 15 minutes, whereas the nPR agonist R5020 had no effect ( Figure 7A ), suggesting that the rapid progesterone effect on TGFβ1 activation was mediated by mPRα.
In addition, signalling pathways involved in this effect were investigated using pertussis toxin (2.5 μg mL -1 ), a cAMP analogue 
| D ISCUSS I ON
mPRs mediate a wide variety of the nongenomic actions of progestins and are localised in the major reproductive tissues of mammals.
The results of the present study clearly demonstrate that mPRs, protein and transcripts are expressed in the rat pituitary gland, as well as in the GH3 cell line. The observation that mPRα would appear to be the most abundant in both models is consistent with previous stud- mPRα expression was also found in rat somatotrophs, although the significance of this finding is currently unknown. On the other hand, the fact that mPRα was found highly expressed in the lactotroph population suggests a physiological role for this receptor in the lactotroph function.
The role of progesterone in the regulation of PRL secretion is controversial. Some studies have reported inhibition, 42 whereas others have reported enhancement of PRL secretion. 43 The findings of the present study support the role of progesterone as a negative modulator. This is in agreement with previous observations of Cramer et al. 44 showing that in vivo progesterone treatment stimulates dopamine release into the hypophysial portal blood in female rats. Similarly, Arbogast et al. 11 reported that progesterone enhances TH activity, which consequently leads to the inhibition of PRL secretion. 11 On the other hand, it is largely assumed that most of the progesterone direct or indirect effects on PRL secretion depend on the activation of the nuclear PRA/B receptors. However, the results of the present study, obtained using an ex vivo assay to avoid hypothalamic influence, demonstrate that either progesterone or the mPRα selective agonist significantly decreased PRL secretion, suggesting the involvement of mPRα in this inhibitory effect. However, because mPRα expression was also found in both somatotrophs and gonadotrophs, we do not discard the paracrine interactions.
To deepen our understanding of the mechanisms involved, stud- Interestingly, this mechanism of action, reducing intracellular cAMP levels through the inhibition of adenylyl cyclase activity, has also been described for dopamine as the primary mechanism by which dopamine suppresses PRL gene expression and PRL release.
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Finally, a novel progesterone inhibitory mechanism mediated by mPRα in lactotrophs was described. It has been shown previously that Moreover, the stimulatory effect of Org OD 02-0 on TGFβ1 activation was found to be a result of the activation of an inhibitory G protein with a consequent reduction in cAMP levels because these actions were blocked by pretreatment with pertussis toxin and the cotreatment with a cAMP analogue (8-Br-cAMP),
respectively. This signalling pathway has been previously proposed for TGFβ1 activation in response to dopamine through D2 receptors coupled to an inhibitory G protein in rat lactotrophs. ANOVA followed by Tukey's honestly significant difference test (n = 3), with 3 replicates each. **P < .001, ***P < .0001 P4 and 02 vs V, respectively; a: P < .001 P4 and 02 vs R5020. (B) Effects of progesterone, Org OD 02-0 (02) and R5020 on PRL release. After treatment, the PRL concentration in the medium was measured by an enzyme immunoassay (EIA). One-way ANOVA followed by Tukey's honestly significant difference test (n = 3), with 3 replicates. **P < .003; a: P < .05 P4 and 02 vs R5020. (C) PTXa (PTX activated, 2.5 μg mL -1 ) effect on
Org OD 02-0 (02) inhibitory effect on PRL secretion in GH3 cell medium measured by EIA. PTXhi (heat-inactivated, 2.5 μg mL -1 ) was used as a control. PRL levels were measured by EIA. Two-way ANOVA, followed by Bonferroni post-hoc test (n = 3), with 3 replicates; significant interaction (P = .0013); *P < .05. (D) Effect of P4, Org OD 02-0 (02) and R5020 treatments on cellular cAMP levels. One-way ANOVA, followed by Tukey's post-hoc test (n = 3), with 3 replicates. ***P < .0004, *P < .05; a: P < .05 P4 and 02 vs R5020. (E) Effect of P4, Org OD 02-0 (02) and R5020 treatments on ERK activation (phosphorylation) in GH3 cells. One-way ANOVA, followed by Tukey's post-hoc test (n = 3), with 3 replicates. *P < .01 
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